Acceleron Pharma entered into research and development agreement with Celgene for Acceleron’s ACE-011 that is in phase 1 clinical trials for treating cancer-related bone loss due to multiple myeloma, bone metastases of solid tumors or cancer treatments. The deal would worth up to US$997 M to Acceleron if specific milestones and sales targets are met along with co-promotion agreement to co-promote the products in North America.